ELI LILLY AND COMPANY Debt Securities, Available-for-sale, Unrealized Loss Position
ELI LILLY AND COMPANY (LLY) had Debt Securities, Available-for-sale, Unrealized Loss Position of $177.20 million as of 2025-09-30, per its 10-Q filed 2025-10-30.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2025-10-30
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $177.20M.
- 2025-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $396.80M.
- 2025-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $435.90M.
- 2024-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $491.20M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2025-09-30 | $177.20M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $396.80M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $435.90M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $491.20M 10-Q · filed 2025-10-30 |
| 2024-09-30 | $367.60M 10-Q · filed 2024-10-30 |
| 2024-06-30 | $508.40M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $477.90M 10-Q · filed 2024-04-30 |
| 2023-12-31 | $452.00M 10-K · filed 2025-02-19 |
| 2023-09-30 | $559.60M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $570.60M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $512.40M 10-Q · filed 2023-04-27 |
| 2022-12-31 | $568.70M 10-K · filed 2024-02-21 |
| 2022-09-30 | $578.80M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $489.20M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $440.60M 10-Q · filed 2022-04-29 |
| 2021-12-31 | $290.20M 10-K · filed 2023-02-22 |
| 2021-09-30 | $208.10M 10-Q · filed 2021-10-27 |
| 2021-06-30 | $164.80M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $170.10M 10-Q · filed 2021-04-30 |
| 2020-12-31 | $11.40M 10-K · filed 2022-02-23 |
| 2020-09-30 | $25.70M 10-Q · filed 2020-10-28 |
| 2020-06-30 | $18.40M 10-Q · filed 2020-07-31 |
| 2020-03-31 | $63.80M 10-Q · filed 2020-05-01 |
| 2019-12-31 | $141.10M 10-K · filed 2021-02-17 |
| 2019-09-30 | $169.10M 10-Q · filed 2019-10-25 |
| 2019-06-30 | $255.80M 10-Q · filed 2019-08-02 |
| 2019-03-31 | $578.60M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $858.60M 10-K · filed 2020-02-19 |
| 2018-09-30 | $816.70M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $898.00M 10-Q · filed 2018-07-25 |
| 2017-12-31 | $4.69B 8-K · filed 2019-10-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |